MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

Sidra Medicine to Host 2024 Precision Medicine Summit

NextEdge Admin

04 Sep 2024

2 min 28 sec

precision medicine,Precision Diagnostics,Genomics,Summit

Sidra Medicine, a Qatar Foundation entity, is set to host the Precision Medicine and the Future of Genomics 2024 Summit (PMFG 2024) from December 3-5 at the Qatar National Convention Centre. The summit will focus on three key pillars: Genomics for All, Precision Diagnostics, and Advanced Therapeutics, bringing together global experts, innovators, and stakeholders to explore the latest advancements in personalized healthcare.

Dr. Iyabo Tinubu-Karch, CEO of Sidra Medicine, emphasized Qatar's leading role in precision medicine, crediting local institutions like Sidra Medicine, Hamad Medical Corporation, and Qatar Precision Health Institute for pioneering therapies and world-class research in genetic and genomic medicine, pediatric rare diseases, and precision health.

Dr. Ammira Akil, lead of the Genetic and Metabolic Disorders Clinical Research Programme at Sidra Medicine and chair of PMFG 2024, highlighted the summit's focus on collaboration and innovation, showcasing advancements in precision medicine, including newborn genome sequencing, population genomics, precise diagnostics, and breakthrough therapies.

With an emphasis on ethical considerations and practical implementation, PMFG 2024 will offer insights into how early genomic information can personalize newborn care, the integration of large-scale genomic advancements into healthcare systems, and targeted treatments for complex and rare diseases.

Prof. Khalid Fakhro, Chief Research Officer at Sidra Medicine, noted Sidra's pivotal role in shaping precision health in the Middle East, particularly through the development of a comprehensive Arab genomic database. The summit will feature Dr. Robert Green from Harvard Medical School as the opening keynote speaker, recognized for his groundbreaking work in newborn genomic sequencing.